Unstable expansions in the Q22-polyglutamine domain of human ATXN2 mediate risks for motor neuron diseases such as ALS/FTLD or cause the autosomal dominant Spinocerebellar Ataxia type 2 (SCA2), but the pathogenesis is not understood and models are unavailable.
The knock-out of ATXN2 in mouse triggers phenotypes of obesity, dyslipidemia, insulin resistance, with hepatic accumulation of lipid droplets and glycogen (4) . In man, the chromosomal ATXN2 locus was linked to obesity, hypertension and diabetes mellitus type 1 (15) . Intriguingly, ATXN2 deficiency not only rescues the lethality of yeast PABP deletion (16), but also shows therapeutic relevance by mitigating the neurodegenerative process in spinocerebellar ataxias and motor neuron disease (17) (18) (19) .
Conversely, phenotypes of neuronal atrophy were documented when ATXN2 contains unstable expansions of its polyglutamine (polyQ) domain that render it more insoluble and aggregation-prone. This domain has Q22 in man, but Q1 in mouse, encoded by CAG. ATXN2 was named by its initial description as the gene mutated in autosomal dominant Spinocerebellar Ataxia type 2 (SCA2), where patients carry pure (CAG)-repeat expansions to sizes ≥33 (20) . Larger expansions lead to younger onset ages, faster progression, more widespread pathology and earlier death (21) (22) (23) . Patients with repeat size Q92 and Q116 had clinical manifestation within the first year of life and showed multi-system atrophy of cerebellum, cerebrum, and brainstem (24, 25) . When an intermediate expansion to [29] [30] triplets occurs, usually with one remaining CAA interruption, it increases the risk to develop motor neuron diseases like ALS (Amyotrophic Lateral Sclerosis) or FTLD (Fronto-Temporal Lobar Dementia) (13) . Also a specific haplotype of single nucleotide polymorphisms in ATXN2 is associated with the risk of ALS (26) . In addition, small expansions of ATXN2 with CAA interruptions were reported to underlie dopaminergic midbrain neuron atrophy in families with Parkinson's disease (PD) (27) .
Currently, there is no curative treatment for SCA2. Recent pharmacological and genetic developments open new opportunities in the near future. Although several models for SCA2
were developed, an authentic mouse model was still lacking. Previous mouse models largely focused on the overexpression of expanded ATXN2 in Purkinje neurons, so they are unsuitable to study extra-cerebellar deficits or the contribution of partial loss-of-function effects. Analysis of these mouse mutants showed that aggregates of ATXN2 protein accumulate in the cytosol rather than in the nucleus (28) . Q58-and Q127-ATXN2 expansions alter neuronal excitability (14, (29) (30) (31) . More recent efforts overexpressed a human Q72-ATXN2 BAC clone containing the physiological promoter and exon-intron structure and showed the G protein signaling factor RGS8 to be dysregulated in cerebellum (18, 32) . We recently published the first knock-in (KIN) mouse where a CAG42-expansion triggers ATXN2 to sequestrate PABP into insolubility in vulnerable brain regions (33) . An induction of the ubiquitination enzyme FBXW8 was observed as a cellular effort to degrade Q42-expanded ATXN2. In addition, partial loss-of-function effects dysregulate calcium homeostasis factors in these mice. Unfortunately, the phenotypes appear only after two years in these Atxn2-CAG42-KIN mice making them unsuitable for studying advanced stages of SCA2.
Here we present a new mouse model that shows authentic SCA2 with fatal course, created via knock-in of the clinically relevant repeat length of 100 CAG-trinucleotides into the murine Atxn2 gene with intact murine promoter and exon-intron structure, in order to preserve its expression regulation.
Results: Generation of the Atxn2-CAG100-KIN and its stability
In order to study the progression of neurodegeneration at multiple levels in an authentic rodent model for SCA2, we created the novel Atxn2-CAG100-knock-in (KIN) mouse line. To this end, a (CAG) 100 repeat with neighboring sequences was synthesized and inserted at position Q156 into the murine Atxn2 exon 1 with flanking loxP sites, employing the homologous recombination strategy shown in Fig. S1A and using previously described targeting vectors (4, 33) . Embryonal stem (ES) cell lines with successful knock-in underwent Flp-mediated excision of the neomycin resistance cassette and verification of the expansion length in heterozygous (CAG1/CAG100) or homozygous (CAG100/CAG100) state by Sanger sequencing and by PCR with Neo-flanking or repeat-flanking primers (Fig. S1B/C, Table S1 ), resulting in a single Atxn2-CAG100-KIN mouse line.
Genotyping with repeat-flanking primers and with DNA-fragment-length-analysis on polyacrylamide gels initially suggested stability of the expansion size, as previously observed in the Atxn2-CAG42-KIN mice (33) . The expanded size of Atxn2 mRNA was confirmed by saturation reverse-transcriptase (RT)-PCR in the cerebellar transcriptome from heterozygous (CAG100Het) and homozygous (CAG100Hom) knock-in mice (Fig. S1D) . The expression level of the expanded Atxn2 mRNA was slightly, but not significantly (p= 0.09) reduced in cerebellum at the age of 20 weeks (Fig. S1E) . Thus, our new mouse mutant recapitulates the repeat expansion of patients at the DNA and the RNA level.
Next, we studied the abundance and solubility of the expanded ATXN2 protein. While WT and the Q42-expanded ATXN2 were soluble in the mild detergents containing RIPA buffer, two antibodies failed to detect the Q100-expanded ATXN2 among RIPA-soluble proteins of cerebellum at the age of 14 months (Fig. S1F-G) . This included analyses with the monoclonal anti-polyQ antibody 1C2, which was raised against a 38Q motif in the N-terminus of nuclear TATA-box-binding protein and recognizes also other expanded polyQ domains, as well as analyses with the monoclonal anti-ATXN2 antibody. The Q100-ATXN2 was weakly detectable, however, in the more insoluble SDS-fraction of cerebellar tissue from CAG100Het and CAG100Hom mice (Fig. S1H) . We take this as evidence that Q100-ATXN2 has a strongly reduced solubility in the cytosol compared to the wildtype protein.
Upon analysis of non-neural peripheral cells, the Q100-expanded ATXN2 was readily detectable by immunoblots of RIPA-soluble proteins from homozygous murine embryonal fibroblasts (MEF), although the amount of expanded ATXN2 corresponded to only 9% of wildtype (WT) (Fig. S1I ). There was no Q100-ATXN2 in the SDS fraction.
Immunocytochemistry of MEF showed a diffuse cytosolic distribution of ATXN2 without aggregation under normal conditions, and its presence in stress granules after arsenite exposure (Fig. S2 ). These observations indicate that the CAG100-expansion reduces the total protein levels of ATXN2. Q100-ATXN2 solubility appears to be lower in cerebellum than in MEF, compatible with the notion that the protein acquires an altered conformation in cells with strong excitability such as neurons. This seems credible in view of the excitation-induced aggregation of polyQ-expanded Ataxin-3 in neurons from patients with Machado-Joseph disease (34) .
In patients, repeat expansions often increase over generations and show a mosaic pattern within somatic cells. To our knowledge, this instability and mosaicism has not been observed in previously generated mouse models of SCA2, while it is a known feature of mice with polyglutamine expansion that model Huntington's disease (35) . Although genotyping had initially suggested repeat stability in our Atxn2-CAG100-KIN mice, periodic testing in successive generations of this colony indicated the occurrence of further expansions and somatic mosaicism, as in SCA2 patients (Fig. 1) .
Offspring contains less female mutants than expected
In the absence of ATXN2, mouse breeding produces less homozygous mutant and less female pups than expected (4) . Also in invertebrates, gender-related reproductive anomalies have been reported, including female sterility in D. melanogaster flies with ATXN2 mutations and abnormal masculinization of the germline in C. elegans worms with ATX-2 deficiency (36, 37) . For these reasons, gender and genotypes were documented among offspring of 25 CAG100Het breeder pairs. The litters contained significantly less homozygous mutants than expected (24% less CAG100Hom than WT pups; p=0.009;  2 test with  2 = 9.384 and df = 2) and less females than expected (12% reduction; p=0.098; 2 test with  2 = 2.731 and df = 2) (Table S2 ). All data suggest that altered ATXN2 functions may impair embryonal development, with some gender-dependence. Thus, the findings constitute evidence for a partial loss-of-function of CAG100-expanded ATXN2 in peripheral tissues and for the high conservation of ATXN2 effects during phylogenesis.
Initial weight excess reverts over time
We followed the mice over time. The CAG100Hom mice showed progressive motor deficits with hindlimb clasping, reduced strength and ataxia (illustrated in Video S1 
CAG100Het mice show a decreased accuracy in their stepping pattern over time
The CAG100Het mice did not show a deficit on the rotarod (Fig. 2F) , despite their loss in body weight (Fig. 2B/C) . To quantify disease progression in CAG100Het mice, we used a more refined task and followed their locomotor behavior over time on the ErasmusLadder.
The ErasmusLadder is composed of alternating higher and lower rungs. Typically, mice prefer to walk on the upper rungs and avoid touching the lower ones (39) . After a week of daily trainings (data not shown) we followed the performance of the mice over time. A similar test for the CAG100Hom mice failed, as they proved to be over-sensitive to the pressurized air indicating the trial timing, hampering performance measurements on the ErasmusLadder at the age of 7 months.
Early symptomatic CAG100Hom show deficient balance and coordination while walking
Since older CAG100Hom mice could not be reliably measured on the ErasmusLadder, we characterized their locomotor phenotype using high-speed videography. To this end, mice were allowed to walk freely on the LocoMouse, essentially consisting of a glass plate between two shelter boxes (40) . During the early symptomatic phase, between 7 and 8 months of age, these homozygotes walked slower than the control mice (p<0.001; Kolmogorov-Smirnov test; 
Compensatory eye movements in CAG100Hom mice
The integrity of oculomotor behavior in early symptomatic CAG100Hom mice was tested using two different reflexes promoting gaze stability: the opto-kinetic reflex (OKR), 
Rhythmic behavior impaired in CAG100Hom mice
Licking is a rhythmic behavior in many animals including mice (47) (48) (49) . 
Progressive brain atrophy and neuronal aggregation
Analysis of the mutant brain revealed atrophy and weight loss for both sexes in CAG100Hom mice, and to a lesser extent also in CAG100Het mice, at the advanced age of 14 months ( hybridization data of unaffected mice at the Allen Brain Atlas. As a novel observation, some ATXN2 expression was also detectable in oligodendrocytes, e.g. of the corpus callosum ( Fig.   S4 ).
Electron microscopy of cerebellar Purkinje neurons detected cytosolic protein aggregates (black arrowheads in Fig. S5 ). In further studies by light microscopy, cytosolic aggregates of ATXN2 were observed in the typical regions affected by neurodegeneration in SCA2, such as cerebellar Purkinje neurons, inferior olivary neurons and pontine nuclei neurons ( Fig. 3E upper rows). Aggregates were also detectable in cerebral cortical and hippocampal neurons and in spinal cord motor neurons, where they were particularly large ( Fig. 3E lower rows) . In all these regions, the cytosolic aggregates were also detectable by immunohistochemistry with the monoclonal anti-polyQ antibody 1C2 (Fig. 3F) . Double immunofluorescence was able to
show the co-localization of ATXN2-positive cytosolic aggregates with ubiquitin signals (Fig.   3G ) and p62 signals (Fig. 3H ) in cerebellum, brainstem and spinal cord, suggesting that they undergo the classical elimination via autophago-lysosomal pathways. Again, particularly large protein aggregates could be observed in spinal cord motor neurons (Fig. 3G , lowest row), in good agreement with the preferential vulnerability of motor neurons in pre-symptomatic stages of human SCA2 (52) . Thus, this Atxn2-CAG100-KIN mouse is an authentic model of the spatio-temporal pattern of pathology known from human SCA2.
Myelinated axon deficits rather than somatodendritic atrophy explain brain weight loss
To identify the cellular and molecular mechanisms that underlie the selective loss of specific neural circuits, we first focused on the cerebellum in view of the early and progressive ataxia in these animals. Histological sections were stained for fluorescence microscopy, with antiCalbindin-1 (CALB1) as marker for Purkinje neurons. While brain autopsies from SCA2 patients show prominent neuron loss after 5-25 years with the disease , and other rodent SCA2 models used overexpression to maximize cell death within the 2-year lifespan of mice (28, 32) , in our KIN model the loss of neuronal cell bodies and dendritic trees was minor upon histological quantification of Purkinje neuron number and molecular layer thickness. This was true even at final stages when the animals displayed severe motor impairment and had to be sacrificed. This observation was validated in cerebellar homogenates by immunoblots for the somatodendritic marker CALB1 and for the dendritic microtubule component TUBA4A, which is responsible for ALS22. Remarkably, the proteins showed only marginal reductions (CALB1 to 87% ± 0.037 mean ± sem, p=0.031; TUBA4A to 90% ± 0.028, p=0.160), although their transcripts upon qPCR analysis showed almost two-fold deficits (Calb1 to 57% ± 0.028, p=0.001; Tuba4a to 56% ± 0.009, p=0.0001) (Fig. S6 ). Histological analysis confirmed that Purkinje neurons in CAG100Hom mice at the age of 14 months, while being largely intact, showed reduced expression of CALB1 in a mosaic pattern. In addition, the loss and dispersal of myelinated axons was detectable (Fig. S7C,D) . This pathology of myelinated axons was similarly observed also by myelin stains of SCA2 patient cerebellum (Fig. S7A,B) .
Evident thinning of the deep cerebellar layers, where climbing and mossy fibers arrive from the brainstem and where Purkinje axons relay the efferent signals, was detected upon myelinspecific staining (Fig. S7E,F ) and upon hematoxylin-eosin histochemistry (Fig. S7G,H ).
Further immunohistochemical analysis with anti-neurofilament antibodies ( 
Identification of molecular correlates for axon and myelin loss at protein level
We carried out surveys of cerebellar tissues via global proteomics with label-free mass spectrometry plus MaxQuant / Perseus bioinformatics as well as via global transcriptomics using Affymetrix Clariom D arrays. They confirmed strong and significant depletion of several key factors of axons and myelin in spite of only marginally altered CALB1 levels and relatively preserved dendritic markers in 14-month-old CAG100Hom mice. While these expression profiles suggested multiple pathways of pathogenesis and have to be evaluated fully with more samples at diverse ages in future manuscripts, we used significant findings from these screenings as a basis for further molecular studies. In the present manuscript they were focused on the validation of consistent downregulations, concerning key protein components of neuronal axons and of oligodendrocyte myelin, employing additional samples with independent methods.
First, essential factors of axonal projections were quantified by immunoblots in cerebellar homogenates, demonstrating their deficiency by normalizations relative to beta-Actin (ACTB)
as general tissue housekeeping protein (Fig. 4) . Nefh/Nefm/Nefl (40% ± 0.015, p=0.0002; 46% ± 0.016, p=0.0005; 48% ± 0.024, p=0.0003, respectively) and Nptn (71% ± 0.015, p=0.001) (see Fig. 4 ).
The downregulation did not affect all axonal and presynaptic components uniformly, given that alpha-synuclein showed strong upregulations at protein (to 243 ± 0.341, p=0.012) and mRNA level (to 169% ± 0.062, p=0.0008) (Fig. 4) . Alpha-synuclein is a component of the SNARE complex that associates with neurotransmitter vesicles in the presynaptic compartment (53) and inhibits excitatory neurotransmission (54).
Second, substantial downregulations were also observed for the main myelin components (Fig. 4) .
RNA-binding ATXN2-Q100 affects further myelin and axon factors at mRNA level
In addition, we observed significant reductions in mRNA levels in the 14-month-old
CAG100Hom cerebellum of several other factors for which no specific antibody was available with sufficient sensitivity to quantify the endogenous protein. For some transcripts, dysregulations were also found in the Atxn2-KO mice, which were studied at the age of 6 months when their progressive obesity phenotype is already evident. Among the relevant myelin components shown in Fig. 4 , a dysregulation in the cerebellum of Atxn2-KO mice was not observed for Cnp or Plp1, but for Mbp (KO to 73% ± 0.035 compared to its WT control, p=0.007). Dysregulation in CAG100 versus KO cerebellum was also documented for Mal (Myelin And Lymphocyte Protein, CAG100 60% ± 0.031 compared to WT, p=0.001, KO 113% ± 0.069, p=0.129) and Mobp (Myelin-Associated Oligodendrocyte Basic Protein) long (CAG100 27% ± 0.027, p=0.0002; KO 71% ± 0.065, p=0.005) versus short transcript (CAG100 39% ± 0.009, p=0.0007, KO 108% ± 0.136, p=0.634) (Fig. 5A ).
Among relevant neuronal components with membrane association, a dysregulation in CAG100 as well as KO cerebellum was observed for components of the extracellular matrix at perineuronal nets and Ranvier nodes, namely Hapln1 (Hyaluronan and Proteoglycan Link Protein 1, CAG100 to 41% ± 0.070, p=0.002; KO 69% ± 0.049, p=0.0005) and Hapln4
(CAG100 54% ± 0.043, p<0.0001; KO 80% ± 0.021, p=0.0003) rather than Hapln2 (CAG100 57% ± 0.067, p=0.005, KO 105% ± 0.098, p=0.640) and Hapln3 (CAG100 86% ± 0.081, p=0.237, KO 87% ± 0.078, p=0.258), as well as the axonal myelination triggers Prnp (Prion Protein, CAG100 75% ± 0.067, p=0.006; KO 133% ± 0.042, p=0.0001) rather than Rtn4
(Nogo-A, CAG100 77% ± 0.022, p<0.0001, KO 94% ± 0.030, p=0.179) (Fig. 5B) .
Among excitability factors that are cytosolic or extracellular, this was also true for Rgs8
(Regulator of G Protein Signaling 8, CAG100 53% ± 0.060, p=0.0004; KO 67% ± 0.049, p=0.023) as a previously reported dysregulation in SCA2 mouse models, and for Klk6
(Kallikrein Related Peptidase 6, CAG100 18% ± 0.017, p=0.0004; KO 73% ± 0.061, p=0.005) as a secreted protease implicated in cell adhesion, in degradation of presynaptic alpha-synuclein and in turnover of oligodendroglial MBP (55) (Fig. 5C ). Given that ATXN2
is a RNA-binding protein and that the above mRNAs involved in axon myelination are prominently affected, this pathway may be crucial at the early stage of cerebellar atrophy in SCA2. Significant dysregulation of the factors schematically depicted in Fig. 5D , and the axonal disconnection probably explains the movement deficits at ages when no neuronal loss is detectable.
Discussion
We generated a genetic mouse model of SCA2, which faithfully reflects the spatial distribution of affected neural pathways, with the preferential vulnerability of motor neurons, vestibular and cerebellar pathways resulting in chronically progressive locomotor deficits.
These phenotypes appear to be triggered by axonal disconnection, demyelination and neural dysfunction rather than by loss of neural cell bodies within the lifespan of our mouse mutants.
As knock-in model it reflects the partial loss-of-function of ATXN2 in peripheral proliferating tissues and at the initial stage of neural pathology, while neurons at older age are stressed by the progressive toxicity of ATXN2 due to the formation of protein aggregates.
This partial loss-of-function is well explained by its strong insolubility in neural tissue and its reduced abundance in peripheral cells. Similar findings of reduced levels and insolubility of polyQ expanded disease proteins were also reported for SCA7 (56) . For polyQ expanded Ataxin-3 it was shown that expression and solubility was normal in induced pluripotent stem cells, fibroblasts or glia cells, but changed to an insoluble aggregated state upon neuronal differentiation and exposure to excitatory stimuli such as glutamate (34) . These previous observations explain our findings that ATXN2-Q100 is quite soluble in fibroblasts, although in much lower amounts, while it goes into immediate insolubility and aggregation in neural tissue. As consequences of this partial loss of function, we observed reduced numbers of female mutants among the offspring, weight excess and hyperactivity during early life.
Interestingly, the changes in body weight show an initial increase followed by progressive decrease not only in our mouse model, but also in SCA2 families upon careful longitudinal assessment (57).
The progressive loss of body weight and brain weight is compatible with an insidious increase of ATXN2-Q100 toxicity due to aggregate formation. ATXN2 is expressed in pancreas and affects the islet beta-cells in their trophic state and their insulin secretion (4), so we assume that ATXN2-Q100 aggregate toxicity affects these postmitotic cells via the known effects of ATXN2 on mTORC1 signaling (7, 58) , thus triggering a depletion of body fat stores.
Similarly, the strong weight reduction of the brain might be explained in large part by a loss in myelin fat. ATXN2 expansion sizes of Q>100 clearly trigger myelination defects also in man, since these SCA2 patients develop widespread leukoencephalopathy upon brain imaging (59) . The importance of demyelination for SCA2 patients with shorter expansions is unclear.
Overall the strongest effect of the CAG100 expansion concerned two glycoproteins that are crucial for myelin-axon adhesion, oligodendroglial MOG and MAG, diminishing their abundance below 20% at the protein level. Importantly, the transcript levels of both factors
were not altered, so this alteration could be a downstream consequence of axon-myelin pathology with excessive turnover of MAG / MOG proteins, or it might be a direct consequence of oligodendrocytic ATXN2 dysfunction impairing the translation of these mRNAs at the rough ER. Both MAG and Nogo-A (encoded by Rtn4) interact as alternative ligands for the receptor NgR1, which modulates neurite outgrowth (60). Nogo-A was transcriptionally downregulated by the toxic ATXN2-Q100. Conversely, a previous report showed the knock-out mouse of Nogo-A to trigger a transcriptional upregulation of ATXN2
and of Ataxin-1 (61), so this adhesion pathology might be among the important primary events of pathogenesis.
Given that the expression of ATXN2 in oligodendrocytes is low in comparison to neurons, it is important to ask which factors that are intrinsic to the axons themselves are dysregulated by the CAG100 expansion. From the study of peripheral nerves of SCA2 patients it is known that axonal degeneration in sensory afferents is among the first objective signs of disease (62) , in agreement with the observations on preferential axonal deficits in our new mouse model.
Interestingly, among all factors studied in the cerebellum only the prion protein (Prnp) mRNA levels were upregulated with significance by the Atxn2-KO as well as conversely downregulated with significance by the CAG100 expansion, suggesting a toxic gain-offunction mechanism. We have previously shown that the deletion of the ATXN2 ortholog PBP1 leads to a downregulation of the prion RNQ1 at the protein level in yeast (12) . Prion protein is an axonal membrane glycolipoprotein and controls myelin maintenance signals via the G-protein coupled receptor Adgrg6 (63) . It is well known that toxic protein aggregates of the prion protein lead to a spongiform encephalopathy in man, cows, sheep and mice (64) .
The CAG100 expansion also had a marked effect on the mRNA and protein levels of the synaptic adhesion factor neuroplastin (NPTN), which is important for the localization of The preferential affection of cell-cell adhesion factors and membrane proteins by the CAG100 expansion might be explained by several aspects of the physiological function of ATXN2.
Firstly, ATXN2 is normally localized at the rough ER rather than smooth ER or free polysomes (6), so it seems to modulate the mRNA translation of factors that are trafficked to the membranes or the extracellular space. Secondly, ATXN2 modulates the availability of glucose, fatty acids and amino acids (10) , so it may modify also the synthesis of glycolipoproteins and of myelin fat. Thirdly, at stress granules ATXN2 is important for the quality control of RNAs that were damaged during cytosolic transport , an event that will occur with high probability for factors that undergo extensive trafficking from the nucleus along the whole axon length to synaptic adhesion sites.
Overall, the resulting neural disconnection and degeneration affects the nervous system with cytosolic inclusion bodies of ATXN2 in the characteristic pattern of olivo-ponto-cerebellar atrophy (OPCA), as was carefully documented in patients (71, 72) . The aggregates are particularly large in spinal motor neurons in our mouse model, and indeed it was recently shown in SCA2 mutation carriers that motor neuron degeneration appears even before the onset of cerebellar ataxia, accompanied by muscle cramps, impaired conduction velocity due to axon demyelination and the loss of subcutaneous fat tissue (52, 73, 74) .
As a result of all these molecular changes, motor deficits develop over time. In previous SCA2 mouse models, performance on the rotarod typically deteriorated over time. The longer the polyQ repeat, the earlier such effects could be observed: as early as 8 weeks for transgenic mice with a long Q128-repeat (29) to as late as 18 months for knock-in mice with a Q42-repeat (33) with onset in-between for repeat sizes midway (14, 28) . Shorter repeats (Q22) did not develop a phenotype on the rotarod (32) . Smaller steps and decreased performance on the beam walk have also been reported (14, 28) . To the best of our knowledge, other types of behavior have not been tested before on mouse models for SCA2. Our behavioral data confirms the aforementioned earlier reports on other SCA2 mouse models regarding the deficits on the rotarod, the stepping pattern and the beam walk. The locomotor phenotype is in line with cerebellar deficits (39, 40) . The grip strength test points towards motor problems, while the intact OKR shows that visual input is not (strongly) affected during the early stage of the disease. Remarkably, the tasks involving the vestibular system showed early deficits, pointing towards dysfunction of the vestibulo-cerebellar system as one of the first hallmarks in the disease process.
In conclusion, the traditional view of SCA2 as a disorder of neural cell loss in the typical OPCA distribution has to be complemented with novel evidence on the prominent vulnerability of spinal motor neurons and the precocious atrophy of axons with their myelin, via dysregulation of adhesion factors. The subsequent neural disconnection underlies the movement deficit, which progresses insidiously from the age of 6 months to a maximal lifespan of 16 months, and triggers the characteristic features of vestibulo-cerebellar and oculomotor dysfunction.
Methods

Body Weight and Behavioral Observations
Heterozygous Atxn2-CAG100-KIN mice were used for breeding. Offspring with CAG100Hom and WT or CAG100Het genotype of similar ages and identical sex were used as case-control pairs for phenotypic comparisons. Sudden death of animals was noted together with the age at death. Mice were weighed before behavioral testing. In contrast to all other measurements, male and female animals were separated for weight analyses due to strong gender-specific weight differences. Brain weight was measured after cervical dislocation, dissection and removal of the olfactory bulb, employing an analytical balance. If not otherwise stated, male as well as female animals were used for phenotype studies without separation. Grip strength was assessed by measuring the peak force of the fore limbs in 10 trials per mouse on an electronic grip strength meter (TSE, Bad Homburg). Paw prints were evaluated by painting the forepaws with a non-toxic red ink, the hind limbs of mice with blue.
The mice were placed at one end of a dark tunnel, so that their walk to the other end will leave paw prints on the white paper that covers the floor (tunnel 6 cm high × 9 cm wide × 40 cm long). Footprint movement patterns were analyzed as described previously (33) 
RNA Isolation and Expression Analysis
Whole brain was removed after cervical dislocation; cerebellum and two hemispheres were dissected into separate tubes and immediately frozen in liquid nitrogen. RNA extraction from cerebellum was performed with TRIzol Reagent (Invitrogen) according to user manual.
DNase digestion was performed using DNaseI Amplification Grade (Invitrogen), and cDNA synthesis from 1 µg of total RNA template was performed by the SuperScript IV VILO kit Membranes were visualized using Li-Cor Odyssey Classic instrument. The image analysis to quantify signal intensities was performed using ImageStudio software. For histological myelin stains, human sections were treated with the modified Heidenhain protocol as described before (76) 
Immunocytochemistry, immunohistochemistry and histological stains
Study approval
The animal studies were performed with ethical approval of the government office in Representative brain photos are shown after animal dissection (seen from above) and (B) after dehydration and embedding in paraffin (as sagittal section). Statistical evaluation of brain weight for WT, heterozygous (HET), and homozygous (HOM) animals was compared separately for male (C) and female (D) animals (for males, reduction to 0.81% vs. 0.55%, p=0.03 vs. 0.001; for females, reduction to 0.87% vs. 0.63%, p<0.00001 vs. <0.00001; tested by ANOVA with multiple testing correction after Bonferroni). Immunohistochemical (IHC) visualization of punctuate or large aggregates, using paraffin-embedded sections and staining for (E) ATXN2 with the monoclonal antibody using DAB detection across various brain regions with known SCA2 pathology and strong Atxn2 expression (black arrows point to cytosolic aggregates), (F) polyQ expansion domains with the monoclonal 1C2 antibody using DAB detection, (G) co-localization of ubiquitin (UBQ) signals and ATXN2 aggregates using double immunofluorescence (white arrows point to yellow co-localization at aggregates), (H) co-localization of the p62 adaptor of ubiquitinated protein aggregates and the ATXN2 signals by double immunofluorescence. Motor neurons and brainstem neurons were more affected by protein aggregates than cerebellar Purkinje neurons. (Kallikrein Related Peptidase 6). Analysis was performed for KO mice at the age of 6 months when obesity is evident, comparing with CAG100Hom mice at the age of 14 months when weight loss is strong. Fold-changes are shown within the bars, t-test was used in general. (D) Schematic representation of the dysregulated transcripts and proteins in the cerebellum of 14-month-old CAG100Hom mouse.
